However, since the activation of TIM-3 pathway may be a barrier to effective PD-1/PD-L1 blockade [21], it could be assumed that double blockade of both immune pathways will maximize the therapeutic effect and prevent the development of adaptive immune resistance by the tumor [28]. This evidence concerns the gene CD274 and neoplasm.